How can the pharmaceutical industry become bigger and stronger? Industry: Need to do "plus and minus"

"Pharmaceutical Network Market Analysis" August 10, a new round of Fortune 500 list was announced, the author after combing found that a total of 21 pharmaceutical companies in the world, including China Pharmaceutical Group and Shanghai Pharmaceutical Group two Chinese pharmaceutical companies.
to see the strength of domestic pharmaceutical companies to improve at the same time, how to become bigger and stronger pharmaceutical industry has also become an industry concern.
industry senior analysis, bigger and stronger pharmaceutical industry, need to do a clever "plus and minus method."
Among them, in addition, including mergers and reorganization, expanding the scale of industry, at the same time need to pay attention to research and development innovation, to strengthen enterprises, subtracting, it is necessary to break homogenization, and through lean management to reduce costs, to become large enterprises.
and as far as domestic pharmaceutical companies are concerned, it is essential to be bigger and stronger, mergers and reorganizations, and continuous investment in research and development innovation.
, this is also the current domestic enterprises in recent years the big action.
Taking Shanghai Pharma as an example, public information shows that Shanghai Pharmaceuticals is a leading pharmaceutical company covering the whole industrial chain of pharmaceutical manufacturing and commerce, and was listed on the main board H-share of the Hong Kong Stock Exchange in 2011, raising about HK$15.5 billion.
It is learned that in the 11 years since the restructuring, Shanghai Pharma has accelerated market-oriented reform through endo-grown growth and foreign mergers and acquisitions, and the company's comprehensive strength has achieved leapfrog development, with business growth of nearly 7 times (a compound annual growth rate of nearly 20%), net profit increasing fourfold, net assets increasing fourfold and market capitalization increasing threefold.
's 2019 annual report showed revenue of RMB186.566 billion, up 17.27% YoY, with the pharmaceutical industry achieving sales revenue of RMB23.490 billion, up 20.70% YoY, growing by more than 20% for the 11th consecutive quarter and entering the 48th place in the global industrial top 50.
In addition, in terms of research and innovation, the number of pharmaceutical research and development personnel in Shanghai in 2019 has exceeded 1,200, and the research and development cost reached 1,350 million yuan, up 27.22% YoY.
statistics, 16 innovative pharmaceutical products (17 adaptives) are currently in the clinical research and clinical trial application stage, 13 generic drug varieties (16 standards) through consistent evaluation.
From the current domestic pharmaceutical industry policy environment, with the volume of procurement, consistent evaluation, medical insurance adjustment and other policies, as well as more foreign-funded pharmaceutical enterprises to enter the market, the layout of deepening, pharmaceutical market competition will intensify, the domestic generic pharmaceutical industry will bid farewell to the era of high gross margin, into an accelerated integration period, not competitive small and medium-sized enterprises are either eliminated or merged.
the market environment, some industry sources pointed out that since the multinational pharmaceutical companies to add code to the Chinese market, the merger and reorganization of domestic pharmaceutical companies accelerated.
" small listed companies in the channel, brand, capital strength there are short board, large enterprises in these areas have more advantages, mergers can help small companies continue to develop.
the future, the pharmaceutical industry big fish eat small fish characteristics will be more obvious.
" In addition, with the current pattern of the pharmaceutical industry constantly reconstructed, innovation will become one of the main themes of the development of the pharmaceutical industry, in the context of the normalization of mining, with innovative strength and research and development capabilities of enterprises are expected to meet new opportunities.
also means that in the future pharmaceutical enterprises need to maintain innovation in order to be invincible, in order to help the pharmaceutical industry sustained and healthy development, so that the industry bigger and stronger.
.